View Older Stories View More Recent Stories

Mar 12, 2018 08:00AM Precision Neuroscience Company Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883
Mar 8, 2018 09:00AM Magenta Therapeutics Strengthens Leadership Team with Promotions, New Hires
Mar 6, 2018 08:00AM Disarm Therapeutics Expands Scientific Advisory Board with Experts in Neurology, Neuropathy, and Axonal Degeneration
Feb 27, 2018 07:00AM Generation Bio Announces $100 Million Series B Financing to Advance GeneWave™ Platform for Re-Dosable Gene Therapy
Feb 22, 2018 07:00AM Surface Oncology Expands Board of Directors
Feb 21, 2018 09:12AM Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer
Feb 13, 2018 11:04AM Form SC 13G Spero Therapeutics, Inc. Filed by: Atlas Venture Associates IX, L.P.
Feb 13, 2018 08:00AM Obsidian Therapeutics Presents Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies
Feb 12, 2018 07:00AM Surface Oncology Promotes Jeff Goater to Chief Executive Officer
Feb 12, 2018 06:54AM Form SC 13G/A ZAFGEN, INC. Filed by: Atlas Venture Fund VII L P
Feb 12, 2018 06:54AM Form SC 13G/A Egalet Corp Filed by: Atlas Venture Fund VII L P
Feb 12, 2018 06:54AM Form SC 13G/A Intellia Therapeutics, Filed by: Atlas Venture Fund IX, L.P.
Feb 6, 2018 06:55AM Atlas Venture Announces That Nessan Bermingham Re-Joins as Venture Partner
Feb 5, 2018 04:25PM Form 13F-HR Atlas Venture Associates For: Dec 31
Feb 1, 2018 07:00AM AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases
Jan 23, 2018 08:00AM Disarm Therapeutics Appoints Thomas Engber as Senior Vice President, Head of Neuropharmacology and Translational Sciences
Jan 22, 2018 08:00AM Harbour BioMed Completes Series A+ Round Financing to Accelerate the Development of Clinical Programs and Company Growth
Jan 8, 2018 01:10PM Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology
Jan 4, 2018 07:00AM Atlas Venture Launches Generation Bio
Dec 19, 2017 09:00AM Disarm Therapeutics Appoints Peter Keller Chief Business Officer
Dec 14, 2017 06:00AM Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways
Dec 6, 2017 06:15AM Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products
Nov 15, 2017 07:00AM Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017
Nov 9, 2017 02:10PM Navitor Pharmaceuticals’ Scientific Founder Makes Seminal Discoveries Related to Role of Nutrient Sensors in mTOR Regulation and Activity
Nov 3, 2017 09:14AM Form 13F-HR Atlas Venture Associates For: Sep 30
Nov 1, 2017 07:50PM Form 3 Atlas Venture Associates For: Nov 01 Filed by: Spero Therapeutics, Inc.
Nov 1, 2017 09:01AM Magenta Therapeutics to Present Clinical Results and Preclinical Research at American Society of Hematology (ASH) Annual Meeting
Oct 30, 2017 07:00AM Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
Oct 26, 2017 08:00AM Magenta Therapeutics Strengthens Leadership Team
Oct 24, 2017 04:01PM Magenta Therapeutics Appoints Alison Lawton, Jeff Albers and Blake Byers to its Board of Directors
Oct 17, 2017 07:00AM Gemini Therapeutics Announces $42.5 Million Series A Financing to Develop Precision Therapeutics in Ophthalmology and Rare Genetic Diseases
Oct 17, 2017 07:00AM Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies
Oct 9, 2017 06:59AM Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine
Oct 3, 2017 08:00AM Cullinan Oncology Secures $150 Million Series A Financing to Build Innovative Development Company
Sep 29, 2017 05:14PM Form SC 13D SYNLOGIC OPERATING CO Filed by: Atlas Venture Fund IX, L.P.
Sep 28, 2017 10:45AM Forbes Names PillPack One of the Next Billion-Dollar Companies
Sep 26, 2017 09:00AM FierceBiotech Names Magenta Therapeutics as one of its “Fierce 15” Biotech Companies of 2017
Sep 19, 2017 07:00AM Disarm Therapeutics Unveils Breakthrough Approach to Treat Patients with Neurological Diseases by Preventing Axonal Degeneration
Sep 18, 2017 07:00AM Rodin Therapeutics Advances Synaptic Resilience Strategy with $27 Million in Financing and Expands Board of Directors
Sep 8, 2017 05:00AM Replimune Raises $55 Million to Advance its Oncolytic Immunotherapy Programs
Aug 30, 2017 04:06PM Form 3 SYNLOGIC, INC. For: Aug 28 Filed by: Atlas Venture Fund IX, L.P.
Aug 28, 2017 09:15AM Synlogic Completes Merger with Mirna Therapeutics
Aug 15, 2017 08:45AM The Trout Group and The Conference Forum Announce Immuno-Oncology 360° Partnership to Fight a Wider Range of Cancers
Aug 3, 2017 04:01PM Bristol-Myers Squibb (BMY) to Acquire IFM Therapeutics
Aug 3, 2017 04:00PM Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity
Jul 18, 2017 01:53PM Form 13F-HR Atlas Venture Associates For: Jun 30
Jul 11, 2017 05:37PM Form 4 Intellia Therapeutics, For: Jul 07 Filed by: Atlas Venture Fund IX, L.P.
Jun 30, 2017 04:04PM Form D Atlas Venture Fund XI,
Jun 29, 2017 06:30AM Atlas Venture Announces $350 Million Fund XI
Jun 20, 2017 08:32AM Xtera(R) Chairman and Chief Strategy Officer to Serve as Programme Chair for SubOptic 2019
View More Recent Stories View Older Stories